Alvotech (ALVO) Depreciation & Amortization (CF) (2021 - 2026)
Alvotech's (ALVO) quarterly Depreciation & Amortization (CF) came in at $10.3 million in Q1 2026, up 24.56% YoY from $8.3 million in Q1 2025, and little changed on a QoQ basis from $10.3 million in Q3 2025.
Alvotech (ALVO) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Alvotech (ALVO) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $10.3 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 24.56% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.5 million (down 46.92% YoY) and the FY2023 annual result came in at $24.2 million, up 18.62% from the prior year.
- Depreciation & Amortization (CF) was little changed at $10.3 million in Q1 2026, from $10.3 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $31.3 million in Q4 2024 to a low of $4.7 million in Q1 2022.
- A 5-year average of $8.9 million and a median of $7.4 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) advanced 3.2% — and 2024, when it jumped 365.44%.
- Tracing ALVO's Depreciation & Amortization (CF) over 5 years: stood at $5.3 million in 2022, then gained by 26.29% to $6.7 million in 2023, then jumped by 365.44% to $31.3 million in 2024, then tumbled by 67.15% to $10.3 million in 2025, then grew by 0.05% to $10.3 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $10.3 million (Q1 2026), $10.3 million (Q3 2025), and $8.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alvotech | 1.30 Bn | 1.30 Bn | 5.09 Mn | 10.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.29 Mn |
| Mar 31, 2026 | 10.29 Mn |
| Sep 30, 2025 | 10.28 Mn |
| Sep 30, 2025 | 10.28 Mn |
| Jun 30, 2025 | 8.90 Mn |
| Jun 30, 2025 | 8.90 Mn |
| Mar 31, 2025 | 8.26 Mn |
| Mar 31, 2025 | 8.26 Mn |
| Dec 31, 2024 | 31.30 Mn |
| Dec 31, 2024 | 31.30 Mn |
| Sep 30, 2024 | 8.40 Mn |
| Sep 30, 2024 | 8.40 Mn |
| Jun 30, 2024 | 7.56 Mn |
| Jun 30, 2024 | 7.56 Mn |
| Mar 31, 2024 | 7.19 Mn |
| Mar 31, 2024 | 7.19 Mn |
| Dec 31, 2023 | 6.73 Mn |
| Dec 31, 2023 | 6.73 Mn |
| Jun 30, 2023 | 6.09 Mn |
| Jun 30, 2023 | 6.09 Mn |